


Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Loodying Disclosure Act of 1995 (Section 5)	
1. Registrant Name King & Spalding LLP	
2. Address Check if different than previously a 1730 Pennsylvania Avenue, N.W.	reported
3. Principal Place of Business (if different from line 2) City: Washington	State/Zip (or Country): D.C. 20006
4. Contact Name Teleph Theodore M. Hester 20	one 5. Senate ID# 21632-618
7. Client Name Self Purdue Pharma L.P.	6. House 1D# 30750051
	year (January 1- June 30) 🗵 OR Year End (July 1 - Dec
9. Check if this filing amends a previously filed version of to 10. Check if this is a Termination Report Termination INCOME OR EXPENSE - Complete Either	n Date 11. No Lobbying Ac
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSE relating to lobbying activities for this report period were:
Less than \$10,000	Less than \$10,000
\$10,000 or more X \$ 40,000 Income (nearest \$20,000)	\$10,000 or more \$Expenses (nearest \$
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client.	our F
	☐ Method A. Reporting amounts using LDA definiti
	☐ Method B. Reporting amounts under section 6033 Internal Revenue Code
	☐ Method C. Reporting amounts under section 162(Internal Revenue Code

Signature		
Printed Name and Title		
LD-2 (REV. 6/98)	Page	<u>1</u> '

~			
Registrant Name	King & Spalding LLP	Client Name _	Purdue Pharma L.P.
engaged in Johnving o	ITY. Select as many codes as non behalf of the client during the sed. Attach additional page(s) as	reporting period. Os.	e general issue areas in which the sing a separate page for each code,
15. General issue are	a code HCR (one per page)		
16. Specific lobbying			
Congressional inves	tigations of OxyContin® and I	legislation to comba	at prescription drug abuse.
17. House(s) of Cong	gress and Federal agencies conta	cted 🗵 Check	if None
18. Name of each ind	lividual who acted as a lobbyist i		overed Official Position (if applicable)
Theodore M. Heste	<u>r</u>		
Beth H. Jafari			
19. Interest of each	foreign entity in the specific issu	es listed on line 16 a	bove
The foreign entity	has an interest in the outcome tion drug abuse.	of congressional in	nvestigations of OxyContin [®] an

Signature		
Printed Name and Title		
LD-2 (REV. 6/98)	Page	<u>2</u>

Registrant Name	King & Spalding LL	P Client Nar	ne <u>Purdı</u>	ue Pharma L.P.
Information Upda	nte Page - Complete ONLY	Where registration information	ation has char	nged.
20. Client new address				
	05 1155 - 1 5 V	20)		
	ce of business (if different from line	State/Zip (or Country)		
City 22. New general description	of client's business or activities			
LOBBYIST UPDA 23. Name of each previ	ATE ously reported individual who	is no longer expected to act	as a lobbyist f	or the client.
Beth Jafari				
ISSUE UPDATE 24. General lobbying is	ssues previously reported that	no longer pertain		
AFFILIATED OF 25. Add the following	RGANIZATIONS affiliated organization(s)			
Na	ıme	Address		Principal Place of E (city and state or c
		_		
26. Name of each prev	riously reported organization t	hat is no longer affiliated with	n the registran	t or client
FOREIGN ENTI 27. Add the following	TIES foreign entities			
Name	Addres	S Principal place (city and state	e of business e or country)	Amount of contribution for lobbying activities
28. Name of each	previously reported foreign	entity that no longer owns.	, or controls,	or, is affiliated with th
client or affiliated	organization	\cap		

Filing #6d6b6d05-ab84-4ba9-92cc-34a59d777a63 - Page 5 of 6

Signature	<u> </u>	Date	August 12, 2	.000
Printed Name and Title	Theodore M. He	ster, Partner		
LD-2 (REV. 6/98)			Page	3